This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
dmmr
A collection of 120 issues
Dual immunotherapy shows durable benefit in MSI-H colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual immunotherapy shows durable benefit in MSI-H colorectal cancer — Journal of Clinical Oncology
Long-term follow-up from the CheckMate 8HW phase 3 trial examined outcomes in patients with MSI-H/dMMR (microsatellite instability-high/mismatch repair-deficient) metastatic colorectal cancer treated with nivolumab plus ipilimumab versus
CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 13, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
CRC Research Update — April 20, 2026
Today's colorectal cancer research highlights
Case Series Reports Bowel Narrowing as Rare Side Effect of Immunotherapy
Skip to content
The CRC Digest
Case Series Reports Bowel Narrowing as Rare Side Effect of Immunotherapy
Doctors report cases of bowel stenosis (narrowing) in dMMR colorectal cancer patients treated with immunotherapy, a side effect that clinicians should monitor. (Clinical Colorectal Cancer)
This content is informational only and does not
CRC Research Update — April 06, 2026
Today's colorectal cancer research highlights
MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient
Skip to content
The CRC Digest
MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient
Exceptional case of synchronous colon cancers with different MMR status provides direct in vivo evidence of ICI responsiveness differences. (Japanese Journal of Clinical Oncology)
This content is informational only and does